Gilead Sciences (GILD) : Analyst Rating Update

Gilead Sciences (GILD) has an average broker rating of 1.94, which is interpreted as a Buy, as rated by 17 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Gilead Sciences (GILD) : Currently there are 14 street experts covering Gilead Sciences (GILD) stock. The most bullish and bearish price target for the stock is $135 and $96 respectively for the short term. The average price target of all the analysts comes to $115.71. The estimated standard deviation from the target is $11.72.

Gilead Sciences (NASDAQ:GILD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $83.64 and $83.33 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $85.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $85.73, notching a gain of 2.19% for the day. The total traded volume was 9,683,817 . The stock had closed at $83.89 on the previous day.

Also, Gabelli & Co initiates coverage on Gilead Sciences (NASDAQ:GILD). The current rating of the shares is Buy, according to the research report released by the firm. The rating by the firm was issued on June 1, 2016. The company shares have dropped -25.72% from its 1 Year high price. On Aug 4, 2015, the shares registered one year high at $120.37 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $84.11 and the 200 Day Moving Average price is recorded at $90.15.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.